Skip to main content
SpringerLink
Log in

Molecular Chemotherapy Approaches

  • Chapter
Cancer Gene Therapy

Part of the book series: Contemporary Cancer Research ((CCR))

  • 1022 Accesses

Abstract

Although many cytotoxic drugs can induce 100% tumor cell kill in vitro, their efficacy in vivo is generally restricted by dose-limiting systemic toxicity. The therapeutic index of these drugs may be improved by regional delivery to the tumor site. This may be achieved by intraarterial, intraperitoneal, intrapleural, intravesical, intrathecal, or intratumoral administration.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Journal Gene Medicine website. http://www.wiley.co.uk/genmed/clinical. Date accessed: 04/22/2003.

  2. Gene Therapy Advisory Committee. Website available at http://www.doh.gov.uk/genetics/gtac/. Date accessed: 04/22/2003.

  3. Collins, J. M. (1984) Pharmacologic rationale for regional drug delivery. J. Clin. Oncol. 2, 498–504.

    PubMed  CAS  Google Scholar 

  4. McClay, E. F. and Howell, S. B. (1990) A review: intraperitoneal cisplatin in the management of patients with ovarian cancer. Gynecol. Oncol. 36, 1–6.

    Article  PubMed  CAS  Google Scholar 

  5. Markman, M., Rowinsky, E., Hakes, T., et al. (1992) Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J. Clin. Oncol. 10, 1485–1491.

    PubMed  CAS  Google Scholar 

  6. Reichman, B., Markman, M., Hakes, T., et al. (1989) Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J. Clin. Oncol. 7, 1327–1332.

    PubMed  CAS  Google Scholar 

  7. Alberts, D. S., Liu, P. Y., Hannigan, E. V., et al. (1995) Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) versus IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG intergroup study [abstract 760]. (INT 0051). Proc. Am. Soc. Clin. Oncol. 14, 273.

    Google Scholar 

  8. Ensminger, W. D., Rosowsky, A., Raso, V., et al. (1978) A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res. 38(11, Pt. 1), 3784–3792.

    PubMed  CAS  Google Scholar 

  9. Kemeny, N., Daly, J., Reichman, B., Geller, N., Botet, J., and Oderman, P. (1987) Intrahepatic or systemic fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann. Intern. Med. 107, 459.

    PubMed  CAS  Google Scholar 

  10. Kerr, D. J., Ledermann, J. A., McArdle, C. S., et al. (1995) Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. J. Clin. Oncol. 13, 2968–2972.

    PubMed  CAS  Google Scholar 

  11. Court, W. S., Order, S. E., Siegel, J. A., et al. (2002) Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest. 20, 613–625.

    Article  PubMed  CAS  Google Scholar 

  12. Okuda, K., Tanaka, M., Shibata, J., et al. (1999) Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol. Rep. 6, 587–591.

    PubMed  CAS  Google Scholar 

  13. Lamm, D. L. and Griffith, J. G. (1992) Intravesical therapy: does it affect the natural history of superficial bladder cancer? Semin. Urol. 10, 39–44.

    PubMed  CAS  Google Scholar 

  14. Tubergen, D. G., Gilchrist, G. S., O’Brien, R. T., et al. (1993) Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Children’s Cancer Group report. J. Clin. Oncol. 11, 520–526.

    PubMed  CAS  Google Scholar 

  15. Curley, S. A., Fuhrman, G. M., Siddik, Z. H., Davidson, B. S., Cleary, K. R., and Cromeens, D. M. (1995) Direct intratumoral injection of a novel collagen matrix gel and cisplatin effectively controls experimental liver tumors. Cancer Res. Ther. Con. 4, 247–254.

    Google Scholar 

  16. Johnson, P. J., Leung, T. W., Vogel, T. J., et al. (2000) Percutaneous administration of cisplatin/epinephrine injectable gel for treatment of intrahepatic lesions of hepatocellular carcinoma [abstract]. Proc. Am. Soc. Clin. Oncol. 35, 1201.

    Google Scholar 

  17. Mok, T. S., Kanekal, S., Lin, X. R., et al. (2001) Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. Cancer 91, 2369–2377.

    Article  PubMed  CAS  Google Scholar 

  18. Wenig, B. L., Werner, J. A., Castro, D. J., et al. (2002) The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 128, 880–885.

    PubMed  Google Scholar 

  19. Kraus, S., Miller, B. H., Swinehart, J. M., et al. (1998) Intratumoral chemotherapy with fluorouracil/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 38, 438–442.

    Article  PubMed  CAS  Google Scholar 

  20. Romano, G., Pacilio, C., and Giordano, A. (1999) Gene transfer technology in therapy: current applications and future goals. Stem Cells 17, 191–202.

    Article  PubMed  CAS  Google Scholar 

  21. Dyer, M. R. and Herring, P. L. (2000) Progress and potential for gene-based medicine. Mol. Ther. 1, 213–224.

    Article  PubMed  CAS  Google Scholar 

  22. Tamura, K., Tamura, M., Ikenaka, K., et al. (2001) Eradication of murine brain tumors by direct inoculation of concentrated high titer-recombinant retrovirus harboring the herpes simplex virus thymidine kinase gene. Gene Ther. 8, 215–222.

    Article  PubMed  CAS  Google Scholar 

  23. Naldini, L., Blomer, U., Gallay, P., et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263–267.

    Article  PubMed  CAS  Google Scholar 

  24. Akkina, R. K., Walton, R. M., Chen, M. L., Li, Q. X., Planelles, V., and Chen, I. S. (1996) High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70, 2581–2585.

    PubMed  CAS  Google Scholar 

  25. Moolten, F. L. (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276–5281.

    PubMed  CAS  Google Scholar 

  26. Sacco, M. G., Mangiarini, L., Villa, A., et al. (1995) Local regression of breast tumors following intramammary ganciclovir administration in double transgenic mice expressing neu oncogene and herpes simplex virus thymidine kinase. Gene Ther. 2, 493–497.

    PubMed  CAS  Google Scholar 

  27. Chen, S. H., Shine, H. D., Goodman, J. C., Grossman, R. G., and Woo, S. L. (1994) Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91, 3054–3057.

    Article  PubMed  CAS  Google Scholar 

  28. DiMaio, J. M., Clary, B. M., Via, D. F., Coveney, E., Pappas, T. N., and Lyerly, H. K. (1994) Directed enzyme prodrug gene therapy for pancreatic cancer in vivo. Surgery 116, 205–213.

    PubMed  CAS  Google Scholar 

  29. Chen, S. H., Chen, X. H., Wang, Y., et al. (1995) Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA 92, 2577–2581.

    Article  PubMed  CAS  Google Scholar 

  30. Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550–1552.

    Article  PubMed  CAS  Google Scholar 

  31. O’Malley, B. W. Jr., Chen, S. H., Schwartz, M. R., and Woo, S. L. (1995) Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 55, 1080–1085.

    PubMed  CAS  Google Scholar 

  32. Fife, K., Bower, M., Cooper, R. G., et al. (1998) Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing. Gene Ther. 5, 614–620.

    Article  PubMed  CAS  Google Scholar 

  33. Vile, R. G. and Hart, I. R. (1993) In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53, 962–967.

    PubMed  CAS  Google Scholar 

  34. Link, C. J. Jr., Levy, J. P., McCann, L. Z., and Moorman, D. W. (1997) Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. J. Surg. Oncol. 64, 289–294.

    Article  PubMed  CAS  Google Scholar 

  35. Samejima, Y. and Meruelo, D. (1995) “Bystander killing” induces apoptosis and is inhibited by forskolin. Gene Ther. 2, 50–58.

    PubMed  CAS  Google Scholar 

  36. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 93, 1831–1835.

    Article  PubMed  CAS  Google Scholar 

  37. Vile, R. G., Nelson, J. A., Castleden, S., Chong, H., and Hart, I. R. (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228–6234.

    PubMed  CAS  Google Scholar 

  38. Izquierdo, M., Martin, V., de Felipe, P., et al. (1996) Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther. 3, 491–495.

    PubMed  CAS  Google Scholar 

  39. Ram, Z., Culver, K. W., Oshiro, E. M., et al. (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3, 1354–1361.

    Article  PubMed  CAS  Google Scholar 

  40. Shand, N., Weber, F., Mariani, L., et al. (1999) A phase 1–2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. 10, 2325–2335.

    Article  PubMed  CAS  Google Scholar 

  41. Rainov, N. G. (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389–2401.

    Article  PubMed  CAS  Google Scholar 

  42. Klatzmann, D., Valery, C. A., Bensimon, G., et al. (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. 9, 2595–2604.

    Article  PubMed  CAS  Google Scholar 

  43. Trask, T. W., Trask, R. P., Aguilar-Cordova, E., et al. (2000) Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 1, 195–203.

    Article  PubMed  CAS  Google Scholar 

  44. Sandmair, A. M., Loimas, S., Puranen, P., et al. (2000) Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 11, 2197–2205.

    Article  PubMed  CAS  Google Scholar 

  45. Herman, J. R., Adler, H. L., Aguilar-Cordova, E., et al. (1999) In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 10, 1239–1249.

    Article  PubMed  CAS  Google Scholar 

  46. Ayala, G., Wheeler, T. M., Shalev, M., et al. (2000) Cytopathic effect of in situ gene therapy in prostate cancer. Hum. Pathol. 31, 866–870.

    Article  PubMed  CAS  Google Scholar 

  47. Shalev, M., Kadmon, D., Teh, B. S., et al. (2000) Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J. Urol. 163, 1747–1750.

    Article  PubMed  CAS  Google Scholar 

  48. Miles, B. J., Shalev, M., Aguilar-Cordova, E., et al. (2001) Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther. 12, 1955–1967.

    Article  PubMed  CAS  Google Scholar 

  49. Todryk, S., Melcher, A., Bottley, G., Gough, M., and Vile, R. (2001) Cell death associated with genetic prodrug activation therapy of colorectal cancer. Cancer Lett. 174, 25–33.

    Article  PubMed  CAS  Google Scholar 

  50. Sung, M. W., Yeh, H. C., Thung, S. N., et al. (2001) Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol. Ther. 4, 182–191.

    Article  PubMed  CAS  Google Scholar 

  51. Sterman, D. H., Treat, J., Litzky, L. A., et al. (1998) Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9, 1083–1092.

    PubMed  CAS  Google Scholar 

  52. Hasenburg, A., Tong, X. W., Rojas-Martinez, A., et al. (2000) Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther. 7, 839–844.

    Article  PubMed  CAS  Google Scholar 

  53. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 93, 1831–1835.

    Article  PubMed  CAS  Google Scholar 

  54. Elshami, A. A., Saavedra, A., Zhang, H., et al. (1996) Gap junctions play a role in the “bystander effect” of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3, 85–92.

    PubMed  CAS  Google Scholar 

  55. Touraine, R. L., Vahanian, N., Ramsey, W. J., and Blaese, R. M. (1998) Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther. 9, 2385–2391.

    PubMed  CAS  Google Scholar 

  56. Loubiere, L., Tiraby, M., Cazaux, C., et al. (1999) The equine herpes virus 4 thymidine kinase is a better suicide gene than the human herpes virus 1 thymidine kinase. Gene Ther. 6, 1638–1642.

    Article  PubMed  CAS  Google Scholar 

  57. Cannon, J. S., Hamzeh, F., Moore, S., Nicholas, J., and Ambinder, R. F. (1999) Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J. Virol. 73, 4786–4793.

    PubMed  CAS  Google Scholar 

  58. Black, M. E., Kokoris, M. S., and Sabo, P. (2001) Herpes simplex virus-1 thymidine kinase mutants created by semirandom sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 61, 3022–3026.

    PubMed  CAS  Google Scholar 

  59. Pantuck, A. J., Matherly, J., Zisman, A., et al. (2002) Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum. Gene Ther. 13, 777–789.

    Article  PubMed  CAS  Google Scholar 

  60. Mullen, C. A., Kilstrup, M., and Blaese, R. M. (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89, 33–37.

    Article  PubMed  CAS  Google Scholar 

  61. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. (1993) In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53, 4619–4626.

    PubMed  CAS  Google Scholar 

  62. Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S. (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91, 8302–8306.

    Article  PubMed  CAS  Google Scholar 

  63. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. (1994) Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 54, 1503–1506.

    PubMed  CAS  Google Scholar 

  64. Ge, K., Xu, L., Zheng, Z., Xu, D., Sun, L., and Liu, X. (1997) Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Int. J. Cancer 71, 675–679.

    Article  PubMed  CAS  Google Scholar 

  65. Lawrence, T. S., Rehemtulla, A., Ng, E. Y., Wilson, M., Trosko, J. E., and Stetson, P. L. (1998) Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res. 58, 2588–2593.

    PubMed  CAS  Google Scholar 

  66. Pierrefite-Carle, V., Baque, P., Gavelli, A., et al. (2002) Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats. Gut 50, 387–391.

    Article  PubMed  CAS  Google Scholar 

  67. Pandha, H. S., Martin, L. A., Rigg, A., et al. (1999) Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol. 17, 2180–2189.

    PubMed  CAS  Google Scholar 

  68. Crystal, R. G., Hirschowitz, E., Lieberman, M., et al. (1997) Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther. 8, 985–1001.

    Article  PubMed  CAS  Google Scholar 

  69. Cunningham, C. and Nemunaitis, J. (2001) A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum. Gene Ther. 12, 1594–1596.

    PubMed  CAS  Google Scholar 

  70. Cao, X., Ju, D. W., Tao, Q., et al. (1998) Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. Gene Ther. 5, 1130–1136.

    Article  PubMed  CAS  Google Scholar 

  71. Khil, M. S., Kim, J. H., Mullen, C. A., Kim, S. H., and Freytag, S. O. (1996) Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin. Cancer Res. 2, 53–57.

    PubMed  CAS  Google Scholar 

  72. Hanna, N. N., Mauceri, H. J., Wayne, J. D., Hallahan, D. E., Kufe, D. W., and Weichselbaum, R. R. (1997) Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 57, 4205–4209.

    PubMed  CAS  Google Scholar 

  73. Uckert, W., Kammertons, T., Haack, K., et al. (1998) Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum. Gene Ther. 9, 855–865.

    Article  PubMed  CAS  Google Scholar 

  74. Chung-Faye, G. A., Chen, M. J., Green, N. K., et al. (2001) In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 8, 1547–1554.

    Article  PubMed  CAS  Google Scholar 

  75. Ohwada, A., Hirschowitz, E. A., and Crystal, R. G. (1996) Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum. Gene Ther. 7, 1567–1576.

    PubMed  CAS  Google Scholar 

  76. Knox, R. J., Boland, M. P., Friedlos, F., Coles, B., Southan, C., and Roberts, J. J. (1988) The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 37, 4671–4677.

    Article  PubMed  CAS  Google Scholar 

  77. Chen, S., Knox, R., Wu, K., et al. (1997) Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse. J. Biol. Chem. 272, 1437–1439.

    Article  PubMed  CAS  Google Scholar 

  78. Knox, R. J., Friedlos, F., Sherwood, R. F., Melton, R. G., and Anlezark, G. M. (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 44, 2297–2301.

    Article  PubMed  CAS  Google Scholar 

  79. Weedon, S. J., Green, N. K., McNeish, I. A., et al. (2000) Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int. J. Cancer 86, 848–854.

    Article  PubMed  CAS  Google Scholar 

  80. McNeish, I. A., Green, N. K., Gilligan, M. G., et al. (1998) Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther. 5, 1061–1069.

    Article  PubMed  CAS  Google Scholar 

  81. Djeha, A. H., Hulme, A., Dexter, M. T., et al. (2000) Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther. 7, 721–731.

    Article  PubMed  CAS  Google Scholar 

  82. Friedlos, F., Quinn, J., Knox, R. J., and Roberts, J. J. (1992) The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink. Biochem. Pharmacol. 43, 1249–1254.

    Article  PubMed  CAS  Google Scholar 

  83. Knox, R. J. (ed.). (1998) Targeted Anti-cancer Therapies: Are They ADEPT or INEPT? University of Greenwich Inaugural Lecture Series, Greenwich, UK.

    Google Scholar 

  84. Bridgewater, J. A., Springer, C. J., Knox, R. J., Minton, N. P., Michael, N. P., and Collins, M. K. (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362–2370.

    Article  PubMed  CAS  Google Scholar 

  85. Chung-Faye, G., Palmer, D., Anderson, D., et al. (2001) Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 7, 2662–2668.

    PubMed  CAS  Google Scholar 

  86. Palmer, D. H., Mautner, V., Mirza, D., et al. (2004) Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol. 22, 1546–1552.

    Article  PubMed  CAS  Google Scholar 

  87. Green, N. K., McNeish, I. A., Doshi, R., Searle, P. F., Kerr, D. J., and Young, L. S. (2003) Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int. J. Cancer 104, 104–112.

    Article  PubMed  CAS  Google Scholar 

  88. Palmer, D. H., Milner, A.E., Kerr, D. J., and Young, L. S. (2003) Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. Br. J. Cancer 89, 944–509.

    Article  PubMed  CAS  Google Scholar 

  89. Lohr, M., Hoffmeyer, A., Kroger, J., et al. (2001) Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357, 1591–1592.

    Article  PubMed  CAS  Google Scholar 

  90. Braybrooke, J. P., Slade, A., Gibson, R., et al. (2002) Phase one study of MetXia-P450 gene therapy for patients with advanced breast cancer or melanoma [abstract]. Proc. Am. Soc. Clin. Oncol. Abstract no. 84.

    Google Scholar 

  91. Cohen, J. L., Boyer, O., Salomon, B., et al. (1997) Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 89, 4636–4645.

    PubMed  CAS  Google Scholar 

  92. Bonini, C., Ferrari, G., Verzeletti, S., et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-vs-leukemia. Science 276, 1719–1724.

    Article  PubMed  CAS  Google Scholar 

  93. Meck, M. M., Wierdl, M., Wagner, L. M., et al. (2001) A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res. 61, 5083–5089.

    PubMed  CAS  Google Scholar 

  94. Wagner, L. M., Guichard, S. M., Burger, R. A., et al. (2002) Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res. 62, 5001–5007.

    PubMed  CAS  Google Scholar 

  95. Caruso, M., Salomon, B., Zhang, S., et al. (1995) Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription. Virology 206, 495–503.

    Article  PubMed  CAS  Google Scholar 

  96. Ohno, T., Gordon, D., San, H., et al. (1994) Gene therapy for ascular smooth muscle cell proliferation after arterial injury. Science 265, 781–784.

    Article  PubMed  CAS  Google Scholar 

  97. Harrell, R. L., Rajanayagam, S., Doanes, A. M., et al. (1997) Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation 96, 621–627.

    PubMed  CAS  Google Scholar 

  98. Carroll, N. M., Chase, M., Chiocca, E. A., and Tanabe, K. K. (1997) The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J. Surg. Res. 69, 413–417.

    Article  PubMed  CAS  Google Scholar 

  99. Rogulski, K. R., Wing, M. S., Paielli, D. L., Gilbert, J. D., Kim, J. H., and Freytag, S. O. (2000) Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. 11, 67–76.

    Article  PubMed  CAS  Google Scholar 

  100. Advani, S. J., Sibley, G. S., Song, P. Y., et al. (1998) Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 5, 160–165.

    Article  PubMed  CAS  Google Scholar 

  101. Vile, R. G., Russell, S. J., and Lemoine, N. R. (2000) Cancer gene therapy: hard lessons and new courses. Gene Ther. 7, 2–8.

    Article  PubMed  CAS  Google Scholar 

  102. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., and Curiel, D. T. (1996) Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. 14, 1574–1578.

    Article  PubMed  CAS  Google Scholar 

  103. Weitman, S. D., Lark, R. H., Coney, L. R., et al. (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52, 3396–3401.

    PubMed  CAS  Google Scholar 

  104. Fisher, K. D., Stallwood, Y., Green, N. K., Ulbrich, K., Mautner, V., and Seymour, L. W. (2001) Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8, 341–348.

    Article  PubMed  CAS  Google Scholar 

  105. Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., and Phipps, M. L. (1997) Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71, 1842–1849.

    PubMed  CAS  Google Scholar 

  106. Reynolds, P. N., Feng, M., and Curiel, D. T. (1999) Chimeric viral vectors—the best of both worlds? Mol. Med. Today 5, 25–31.

    Article  PubMed  CAS  Google Scholar 

  107. Zhang, W. W. (1999) Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6, 113–138.

    Article  PubMed  CAS  Google Scholar 

  108. Alemany, R., Lai, S., Lou, Y. C., Jan, H. Y., Fang, X., and Zhang, W. W. (1999) Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. 6, 21–25.

    Article  PubMed  CAS  Google Scholar 

  109. Bartlett, J. S. and Samulski, R. J. (1998) Fluorescent viral vectors: a new technique for the pharmacological analysis of gene therapy. Nat. Med. 4, 635–637.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CR UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK

    Daniel H. Palmer

  2. Department of Clinical Pharmacology, University of Oxford, Oxford, UK

    David J. Kerr

Authors
  1. Daniel H. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

  2. Division of Human Gene Therapy, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

  3. Division of Human Gene Therapy, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

  4. Division of Human Gene Therapy, Department of Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Palmer, D.H., Kerr, D.J. (2005). Molecular Chemotherapy Approaches. In: Curiel, D.T., Douglas, J.T. (eds) Cancer Gene Therapy. Contemporary Cancer Research. Humana Press. https://doi.org/10.1007/978-1-59259-785-7_8

Download citation

Publish with us

Policies and ethics

Search

Navigation